Navigation Links
MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
Date:11/14/2007

e meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These statements are based on MiddleBrook's current expectations and assumptions. These statements are not guarantees of future performance and are subject to a number of risks and uncertainties that would cause actual results to differ materially from those anticipated. The words, "believe," "expect," "intend," "anticipate," and variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking. Statements in this announcement that are forward-looking include, but are not limited to, statements about the Company's product development and commercialization schedule, including, particularly, future plans with respect to its Amoxicillin PULSYS products; any statements regarding Dr. Rudnic's comments and expectations concerning the Company; the Company's initiatives to develop improved antibiotics; the Company's existing and anticipated collaborative agreements; and any financial forecasts and projections for 2007 and thereafter included under the Financial Guidance section of this announcement.

The actual results realized by MiddleBrook could differ materially from these forward-looking statements, depending in particular upon the risks and uncertainties described in the Company's filings with the Securities and Exchange Commission. These include, without limitation, risks and uncertainties relating to the Company's financial results and the ability of the Company to (1) raise additional capital and continue as an ongoing concern, (2) increase Keflex 750 sales, (3) obtain FDA approval for its Amoxicillin PULSYS product candidate, (4) successfully reduce costs, (5) maintain compliance with provisions under its financing arrangements, (6) reach profitability, (7) prove that the preliminary findings for its product candidates are vali
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Santa Rosa, CA (PRWEB) , ... August 30, ... ... High Intensity Focused Ultrasound (HIFU) medical devices for the treatment of prostate cancer, ... – introduced this summer at the treatment center in Puerto Vallarta, Mexico. ...
(Date:8/29/2015)... PA (PRWEB) , ... August 29, 2015 , ... ... said one of two inventors from Miller Place, N.Y. "I specialize in manual ... and discomfort. In addition, it can be used for additional muscle dysfunction throughout ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 , ... ... unofficial end of summer (which astronomically, officially ends on September 22nd this year). For ... summer-induced cyber security hangovers linger on which could prove far more costly than a ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... to freely market and sell Arterosil and Arterosil HP, and that all claims ... (DHS) sued Vascular Health Sciences, LLC (VHS) in the United States District Court ...
(Date:8/28/2015)... New Port Richey, FL (PRWEB) , ... August 28, 2015 , ... ... that while many potential workers are qualified for the position they are applying for, ... work. Because of this, many employers are considering altering drug testing policies in order ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... a deep breath, and then his legs become contorted into ... moves into an arch in the shape of the letter ... for that matter. His instructor does the work for him, ... of contorting and moving, with ironically little work on the ...
... shown that Only approximately 50% of patients in developed ... chronic diseases and this is even lower in developing ... long-term treatment medication of ,diseases such as cardiovascular diseases, ... of the WHO’s newly published report entitled "Adherence to ...
... traffic ticket you just received could be preventing a fatal ... researchers who studied the impact of traffic convictions on the ... show drivers run a significantly lower risk of getting in ... when compared to other months when no conviction took place., ...
... that early detection is important for preventing disease. In the ... with no tricks, just light.Jim Hattaway is a nine-year ,survivor ... despite a delayed diagnosis. ,"They never found a primary, which ... forms on the ,surface of the skin. It had already ...
... the Mediterranean diet is a simple recipe for good health. ... that those consuming the classic diet -- rich in olive ... moderate amount of wine -- lived longer than those who ... the more likely you are to live longer," said Dr. ...
... angry about something, let it out and it ... study shows people with headaches internalize their anger ... adults who participated in the study, 171 suffered ... anger experienced in daily life), internalized anger, hostility, ...
Cached Medicine News:Health News:The 'lazy man's yoga" 2Health News:In Chronic Diseases - Poor compliance of Patients with drug treatment 2Health News:Eat Like a Greek for Good Health 2
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Quetiapine Market, ... Developed by AstraZeneca plc, quetiapine (under the trade ... the treatment of schizophrenia. Approved by CFDA to ... the Catalogue of Drugs for the Basic National ...
(Date:8/28/2015)... 2015 The scientific team of a ... of the leading academics in the field of aging Prof. ... in life extension for model animals - 10 fold for ... and age-related diseases, primarily, around the stability and stress resistance ... published as "Stability analysis of a model gene network links ...
(Date:8/28/2015)... FARUM, Denmark and ATLANTA ... July 31, 2015 the US Food and Drug Administration (FDA) ... Major Depressive Disorder in adult patients who have failed to ... episode. TMS is a non-invasive technique for stimulating neural tissue ... from Major Depressive Disorder. The procedure has been proven safe ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
... ZeaVision, LLC announced two internal promotions as the ... its leading EyePromise® nutraceutical products featuring ... to President effective immediately from his previous role of ... appointment to the ZeaVision Executive Board. Founder, ...
... Sept. 1 In recognition of September,s designation as ... Pain Physicians (ASIPP) today announced that it is planning ... life for the approximately 75 million Americans suffering from ... this outreach, ASIPP has developed a consumer section on ...
Cached Medicine Technology:Nutraceutical Leader Announces Internal Promotions of Key Personnel 2American Society of Interventional Pain Physicians (ASIPP) Promotes Patient Education and Outreach Initiatives During National Pain Awareness Month 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: